Kathryn V. Papp, Sarah Tomaszewski Farias, Marjorie Howard, Amber Thro, Tiia Ngandu, Brad Caudle, Bonnie C. Sachs, Michelle Chan, Kristin R. Krueger, Elizabeth R. T. Hartman, Athene Lee, Michele K. York, Marie T. Austin, Kathryn E. Demos, Thomas M. Holland, Xiaoyan Leng, Rema Raman, Heather M. Snyder, Maria C. Carrillo, Rachel A. Whitmer, Mark A. Espeland, Laura D. Baker, the US POINTER Study Group
{"title":"基线认知、人口统计学、生活方式和心血管危险因素在美国指针","authors":"Kathryn V. Papp, Sarah Tomaszewski Farias, Marjorie Howard, Amber Thro, Tiia Ngandu, Brad Caudle, Bonnie C. Sachs, Michelle Chan, Kristin R. Krueger, Elizabeth R. T. Hartman, Athene Lee, Michele K. York, Marie T. Austin, Kathryn E. Demos, Thomas M. Holland, Xiaoyan Leng, Rema Raman, Heather M. Snyder, Maria C. Carrillo, Rachel A. Whitmer, Mark A. Espeland, Laura D. Baker, the US POINTER Study Group","doi":"10.1002/alz.70216","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Validation of the primary cognitive composite and baseline cognitive characteristics are presented for the US-Study-to-Protect-Brain-Health-Through-Lifestyle-Intervention-to-Reduce-Risk (US POINTER).</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>US POINTER is a multicenter, randomized clinical trial of two lifestyle interventions testing cognitive benefit in older adults without significant cognitive impairment but at-risk for decline due to well-established factors. Cognition is measured using a global cognitive composite (US POINTER modified Neuropsychological Test Battery-PmNTB).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>The PmNTB is a valid cognitive composite, exhibiting good psychometric properties and tracking with other established outcomes. Among the 2111 enrolled participants (mean age = 68.2 years, 69% women, 31% from race and ethnic minoritized groups), demographic characteristics alone (age, sex, education, race, ethnicity) explained more variance in cognition measured using the PmNTB (25.94%) compared with cardiovascular and family history risk factors combined (added < 3% explained variance).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>In a large diverse older adult cohort, demographic features rather than well-established risks for cognitive decline correlate with baseline global cognition.</p>\n \n <p>Clinical trial registration number: NCT03688126</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Demographic characteristics explain baseline cognition in at-risk older adults.</li>\n \n <li>The POINTER Modified Neuropsychological Test Battery (PmNTB) is a valid measure.</li>\n \n <li>Worse cognition tracks with E4+, high HbA1c, current smoking, Framingham heart risk.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 7","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70216","citationCount":"0","resultStr":"{\"title\":\"Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTER\",\"authors\":\"Kathryn V. Papp, Sarah Tomaszewski Farias, Marjorie Howard, Amber Thro, Tiia Ngandu, Brad Caudle, Bonnie C. Sachs, Michelle Chan, Kristin R. Krueger, Elizabeth R. T. Hartman, Athene Lee, Michele K. York, Marie T. Austin, Kathryn E. Demos, Thomas M. Holland, Xiaoyan Leng, Rema Raman, Heather M. Snyder, Maria C. Carrillo, Rachel A. Whitmer, Mark A. Espeland, Laura D. Baker, the US POINTER Study Group\",\"doi\":\"10.1002/alz.70216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>Validation of the primary cognitive composite and baseline cognitive characteristics are presented for the US-Study-to-Protect-Brain-Health-Through-Lifestyle-Intervention-to-Reduce-Risk (US POINTER).</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>US POINTER is a multicenter, randomized clinical trial of two lifestyle interventions testing cognitive benefit in older adults without significant cognitive impairment but at-risk for decline due to well-established factors. Cognition is measured using a global cognitive composite (US POINTER modified Neuropsychological Test Battery-PmNTB).</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>The PmNTB is a valid cognitive composite, exhibiting good psychometric properties and tracking with other established outcomes. Among the 2111 enrolled participants (mean age = 68.2 years, 69% women, 31% from race and ethnic minoritized groups), demographic characteristics alone (age, sex, education, race, ethnicity) explained more variance in cognition measured using the PmNTB (25.94%) compared with cardiovascular and family history risk factors combined (added < 3% explained variance).</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>In a large diverse older adult cohort, demographic features rather than well-established risks for cognitive decline correlate with baseline global cognition.</p>\\n \\n <p>Clinical trial registration number: NCT03688126</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Demographic characteristics explain baseline cognition in at-risk older adults.</li>\\n \\n <li>The POINTER Modified Neuropsychological Test Battery (PmNTB) is a valid measure.</li>\\n \\n <li>Worse cognition tracks with E4+, high HbA1c, current smoking, Framingham heart risk.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 7\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70216\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.70216\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70216","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
介绍了US- study -to- protection - brain - health - through - lifestyle - intervention -to- reduce - risk （US POINTER）的主要认知组合和基线认知特征的验证。方法：美国POINTER是一项多中心、随机临床试验，采用两种生活方式干预，测试无明显认知障碍但存在因既定因素导致认知能力下降风险的老年人的认知益处。认知使用全局认知复合（美国指针修正神经心理测试电池- pmntb）进行测量。结果PmNTB是一种有效的认知复合物，具有良好的心理测量特性和与其他既定结果的跟踪性。在2111名入组的参与者中（平均年龄为68.2岁，69%为女性，31%来自种族和少数民族群体），单独的人口统计学特征（年龄、性别、教育程度、种族、民族）与心血管和家族史风险因素相结合(添加<；3%解释方差)。在一个大型的多样化的老年人队列中，人口统计学特征而不是公认的认知能力下降风险与基线全球认知能力相关。临床试验注册号：NCT03688126强调人口统计学特征解释了高危老年人的基线认知。POINTER改良神经心理测试组（PmNTB）是一种有效的测量方法。认知能力差与E4+、高HbA1c、当前吸烟、Framingham心脏病风险相关。
Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTER
INTRODUCTION
Validation of the primary cognitive composite and baseline cognitive characteristics are presented for the US-Study-to-Protect-Brain-Health-Through-Lifestyle-Intervention-to-Reduce-Risk (US POINTER).
METHODS
US POINTER is a multicenter, randomized clinical trial of two lifestyle interventions testing cognitive benefit in older adults without significant cognitive impairment but at-risk for decline due to well-established factors. Cognition is measured using a global cognitive composite (US POINTER modified Neuropsychological Test Battery-PmNTB).
RESULTS
The PmNTB is a valid cognitive composite, exhibiting good psychometric properties and tracking with other established outcomes. Among the 2111 enrolled participants (mean age = 68.2 years, 69% women, 31% from race and ethnic minoritized groups), demographic characteristics alone (age, sex, education, race, ethnicity) explained more variance in cognition measured using the PmNTB (25.94%) compared with cardiovascular and family history risk factors combined (added < 3% explained variance).
DISCUSSION
In a large diverse older adult cohort, demographic features rather than well-established risks for cognitive decline correlate with baseline global cognition.
Clinical trial registration number: NCT03688126
Highlights
Demographic characteristics explain baseline cognition in at-risk older adults.
The POINTER Modified Neuropsychological Test Battery (PmNTB) is a valid measure.
Worse cognition tracks with E4+, high HbA1c, current smoking, Framingham heart risk.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
